sentence: Oocytes, which are highly sensitive to DNA damage caused by certain cancer treatments, can be protected from radiation-induced death by an inhibitor 20 of the checkpoint protein CHK2.
INTRODUCTION

55
It is of paramount importance that organisms minimize the transmission of deleterious mutations to their offspring. Accordingly, sensitive mechanisms have evolved to eliminate germ cells that have sustained certain threshold amounts of DNA damage (HEYER et al. 2000; SUH et al. 2006; BOLCUN-FILAS et al. 2014; PACHECO et al. 2015) . Under normal circumstances, this is desirable. However, because women are 60 born with a finite number of oocytes, environmental factors that cause DNA damage to oocytes can result in primary ovarian insufficiency (POI), sterility, and ovarian failure. This is a crucial issue for cancer patients undergoing certain types of chemotherapy or radiation therapy (WOODRUFF 2007) . For example, POI occurs in nearly 40% of all female breast cancer survivors (OKTAY et al. 2006) . The resulting premature ovarian 65 failure has major impact in a women's life, both physiologically and emotionally. As the life expectancy of cancer survivors increases, so does the need to address the adverse outcomes to fertility. Therefore, the ability to inhibit oocyte death and preserve fertility, in both pre-pubertal cancer patients and premenopausal women, would have a major impact on survivors' lives. 70
At present, cancer patients have few options regarding fertility preservation ("oncofertility") before treatment, and most involve invasive surgical procedures such as extraction of oocytes or ovarian tissue for cryopreservation, or IVF followed by embryo cryopreservation (REDIG et al. 2011; SALAMA AND MALLMANN 2015; KIM et al. 2016) . Not only are these invasive, but also they necessitate a delay in cancer treatment. An 75 alternative is to co-administer drugs that protect oocytes from chemotherapy at the time of treatment. For example, based on the knowledge that inactivation of the "TA" isoform of the DNA damage checkpoint gene Trp63 (TP63 in humans, also known as p63; the TA isoform of the protein will be referred to as TAp63) prevents radiation-induced oocyte loss in mice (SUH et al. 2006) , it was reported (GONFLONI et al. 2009 ), but later 80 challenged (KERR et al. 2012) and counter-argued (MAIANI et al. 2012) , that the tyrosine kinase inhibitor imatinib (Gleevec) is effective in protecting oocytes. Even if imatinib proves to have such activity, it is a relatively promiscuous kinase inhibitor that blocks, among other targets, the receptor tyrosine kinase KIT that functions in germline stem
cells (LEE AND WANG 2009). 85
We previously reported that mouse CHK2 is a key component of the meiotic DNA damage checkpoint, and that deletion of Chk2 prevented irradiation-induced killing of postnatal oocytes (BOLCUN-FILAS et al. 2014) . We also showed that the CHK2 kinase phosphorylates both p53 (formally TRP53; TP53 in humans) and TAp63 in oocytes to activate these proteins (and stabilize TRP53). Therefore, the deletion of Chk2 effectively 90 impairs the activation of these two downstream effectors, which are both needed to trigger efficient oocyte elimination (BOLCUN-FILAS et al. 2014 ). More importantly, damaged oocytes that survived in the absence of CHK2 produced healthy pups suggesting that the inflicted DNA damage was repaired (BOLCUN-FILAS et al. 2014) . The resistance of Chk2 -/oocytes to otherwise lethal levels of ionizing radiation (IR) 95 prompted us to explore whether chemical inhibition of CHK2 would be effective at preventing radiation-induced oocyte death, and thus constitute a potential option for preserving ovarian function in women undergoing cancer therapy. Here we show that transient chemical inhibition of CHK2 prevents follicle loss and allows for the production of healthy offspring. 100
Results and Discussion
Irradiation of ovaries induces CHK2-dependent phosphorylation of TAp63 in oocytes, and this phosphorylation is essential for triggering their death (SUH et al. 2006; BOLCUN-FILAS et al. 2014) . CHK2 is a key component of the DNA damage response 105 pathway that responds primarily to DNA double strand breaks (DSBs), lying downstream of the apical kinase ATM (ataxia telangiectasia mutated). Members of the ATM>CHK2>p53/p63 pathway have been implicated as potential anti-cancer drug targets sensitizing cancer cells to genotoxic therapies, and chemical inhibitors have been developed against CHK2 (GARRETT AND COLLINS 2011), which, when deleted in 110 mice, causes only minor phenotypic consequences (TAKAI et al. 2002) . We therefore tested whether a well characterized CHK2 inhibitor 2-(4-(4-Chlorophenoxy)phenyl)-1Hbenzimidazole-5-carboxamide-hydrate (designated "Chk2 inhibitor II" by the manufacturer, referred to here as "CHK2iII") could mimic the oocyte-protective effect of genetic Chk2 deletion, and if it could do so in a non-toxic manner. 115
We employed an organ culture paradigm to control dosages, penetration and timing of drug delivery to the ovary. Using dose ranges based upon published data (ARIENTI et al. 2005 ) and the manufacturer's recommendations, we first tested the ability of CHK2iII to block phosphorylation of TAp63 in irradiated ovaries, and to block the stabilization of p53, which is normally rapidly degraded in cells unless stabilized by DNA-damage-120 induced phosphorylation by proteins including CHK2 (CHEHAB et al. 2000; HIRAO et al. 2000) . We used ovaries from 5 days postpartum (dpp) females to ensure that oocytes were in the dictyate arrest stage of meiosis, residing within primordial follicles.
Explanted ovaries were cultured for two hours in the presence of 0, 10 or 20µM CHK2iII, then subjected (or not) to 3 Gy of IR, a level that not only kills oocytes, but also causes 125 extensive TRP53 stabilization and TAp63 phosphorylation (SUH et al. 2006; BOLCUN-FILAS et al. 2014) . Ovaries were harvested three hours later for protein extraction and western blot analysis. In non-irradiated ovaries, TAp63 remained unphosphorylated and TRP53 was undetectable ( Fig. 1) . Irradiation in the absence of inhibitor led to robust TRP53 stabilization, and all TAp63 was shifted to a higher mobility, which is known to 130 be due to phosphorylation (SUH et al. 2006; LIVERA et al. 2008) . Addition of 10µM and 20µM CHK2iII led to partial and complete inhibition of TAp63 phosphorylation, respectively, and also progressively decreased TRP53 levels (Fig. 1 ). This confirms that CHK2iII treatment rapidly acts to prevent activation of two pro-apoptotic factors in the ovary. 135
Next, we tested whether CHK2iII could permanently protect oocytes from a lower dose of radiation (0.4 Gy) that normally kills all oocytes within 2 days (SUH et al. 2006; BOLCUN-FILAS et al. 2014) but is far below levels (>5 Gy) lethal to whole animals.
Ovaries were cultured in media supplemented with 0, 5, 10, or 20 µM of inhibitor for 2 hours before irradiation. Following IR exposure, ovaries were cultured 2 more days with 140 media changes as delineated in Fig. 2a , after which the drug was removed from the medium. This protocol of media changes with drug replenishment was optimized for oocyte survival. Seven days after irradiation (and 5 days after removal of CHK2iII, oocyte survival was assessed by co-immunolabeling of histological sections ( Fig. S1 ) and of whole mounts, with the cytoplasmic germ cell marker MVH and oocyte nuclear 145 marker p63 (Figs. 2b, S2a, and Supplemental movies M1, M2, M3) . Under these conditions the inhibitor was well tolerated, and oocyte survival in unirradiated ovaries was not compromised ( Fig. S2b and Supplemental movies M4, M5).
Remarkably, though 10µM CHK2iII only partially inhibited TAp63 phosphorylation induced by 3Gy of IR ( Fig. 1) , it dramatically improved oocyte survival in ovaries 150 exposed to 0.4Gy of IR, a level sufficient to trigger TAp63 phosphorylation and eliminate nearly all primordial follicles in ovaries (Fig 2b,c; S3 ) (SUH et al. 2006; BOLCUN-FILAS et al. 2014) . A small but significant protective effect was also observed with 5µM CHK2iII (p=004, Fig. 2b,c) .
To assess if oocytes protected by CHK2iII from otherwise lethal levels of irradiation 155 were capable of ovulation, fertilization, and subsequent embryonic development, we performed intrabursal transfers of irradiated ovaries (0.4 Gy) into histocompatible (strain C3H) agouti females. These recipient females were first sterilized at 7 dpp by exposure to 0.5Gy of IR. Once females were eight weeks old, sterility was verified by housing them with fertile males for at least eight weeks. The IR-induced oocyte death led to 160 premature ovarian failure, yielding sufficient intrabursal space without the need to physically remove the vestigial ovaries before ovary transfer. These recipients were 16 weeks of age at the time of surgery. Three cultured ovaries, derived from black female animals also of strain C3H (see Methods for additional information), were placed into each bursa. Once the transferred donor ovary reached 8 weeks of age (with respect to the time 170 at which it was explanted), the recipient females were mated to proven fertile C3H black (a/a) males for three months, and monitored for litters and the coat colors of offspring.
Only females that received CHK2iII-treated ovaries delivered progeny, all of which were black, confirming that they were produced from fertilization of oocytes ovulated from donor ovaries (Fig. 3b and c) . All offspring had no visible abnormalities that would 175 suggest inheritance of gross chromosomal abnormalities (BOLCUN-FILAS et al. 2014) .
The viability of these animals indicated that even though oocytes have sensitive checkpoint mechanisms rendering them vulnerable to low levels of DNA damage, they are capable of repairing damaged DNA in a manner compatible with normal embryogenesis. 180
Our results provide proof-in-principle for the strategy of targeting the CHK2dependent DNA damage checkpoint pathway for preventing loss of ovarian reserveand thus ovarian failure in prepubertal or premenopausal cancer patients undergoing therapies that are toxic to oocytes. Importantly, checkpoint inhibitors have already been explored as potential anticancer therapies, thus substantial information is already 185 available on members of this drug class (ANTONI et al. 2007 ; GARRETT AND COLLINS 2011). Nevertheless, it remains to be seen whether systemic administration of CHK2iII, or other CHK2 inhibitors, can achieve similar oocyte-protective efficacy against IR-or drug-induced DSBs in vivo. Additionally, it will be important to conduct more thorough studies of potential genetic risks associated oocytes rescued from DNA damage-190 induced death by checkpoint inhibition.
MATERIALS AND METHODS
Mice
Mice were obtained from The Jackson Laboratory, strains C3HeB/FeJ, stock # 000658 (agouti mice, homozygous dominant for coat color (A/A)) and C3FeLe.B6-a/J, stock # 000198 (black mice, recessive for coat color, (a/a)). Cornell's Animal Care and Use Committee approved all animal usage, under protocol 2004-0038 to JCS.
Organ Culture
Ovaries were cultured using an adaptation of a published method (LIVERA et al. 2008 ). Briefly, ovaries were collected from five day postpartum (dpp) C3FeLe.B6-a/J mice, and, following removal from the bursa, placed into cell culture inserts (Millicell; pore size: 8µm; diameter: 12mm) pre-soaked in ovary culture media: MEM supplemented with 10% FBS, 25mM HEPES pH=7.0, 100 units/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml Fungizone, 1%DMSO, and CHK2 inhibitor. The inserts were placed into 24 well plates (Model MD24 ThermoFisher) with carriers for the inserts.
Sufficient media was added to keep organs moist, but not completely submerged.
Organs were incubated at 37°C, 5% CO 2 and atmospheric O 2 .
Drug Treatment
CHK2iII (CalBiochem 220486) was prepared as 1mM and 2mM stock solutions in DMSO and kept frozen at -20°C. Media containing the desired concentration of inhibitor was prepared shortly before use, assuring that the DMSO concentration was constant (1%DMSO) throughout the different conditions. Explanted ovaries were pre-incubated for 2 hours in warm (37°C) media containing the desired concentration of inhibitor or 1% DMSO alone before being subjected to ionizing radiation in a 137 cesium irradiator with a rotating turntable. Figure 2a presents the media change regimen, with the first replacement being immediately after irradiation. The ovaries were cultured for either 3 hours before being processed for western blot analysis (to detect DNA damage responses), or 7 days followed by either fixation and immunostaining (to quantify oocyte survival), or ovary transplant surgery into sterile agouti females.
Western Blot Analyses and Antibodies
Ovary protein lysates, immunoblotting, probing and detection were conducted as described (BOLCUN-FILAS et al. 2014) . Primary antibodies and dilutions used were: mouse anti-p63 (1:500, 4A4, Novus Biologicals); rabbit anti-p53 (1:300, Cell Signaling #9282); mouse anti-β-actin (1:5000, Sigma) and rabbit anti-MVH (1:1000, Abcam).
Secondary antibodies used were: Immuno Pure goat anti-mouse IgG(H+L) peroxidase conjugate (1:5000, ThermoFisher) and goat anti-rabbit IgG HRP-linked antibody (1:5000, Cell Signaling).
Immunofluorescence
Cultured ovaries were fixed in 4% paraformaldehyde/PBS at 4°C overnight, and then washed and stored in 70% ethanol. Ovaries were either embedded in paraffin and sectioned at 5µm for immunostaining or subjected to whole mount immunostaining and clearing. For the standard immunofluorescence, slides were deparaffinized and re-hydrated prior to antigen retrieval using sodium citrate buffer. Slides were blocked with 5% goat serum (PBS/Tween 20), incubated at 4°C overnight with aforementioned primary antibodies (anti-p63 @ 1:500; anti-MVH @ 1:1000), and subsequently incubated with Alexa Fluor® secondary antibodies for one hour and Hoechst dye for 5 minutes. Slides were mounted with ProLong Anti-fade (Thermo-Fisher) and imaged.
Ovary transfer surgery
Agouti females were radio-sterilized with 0.5Gys of radiation at one week of age. Once eight weeks old, females were housed with males known to be fertile. After eight weeks, and two days prior to ovary transfer surgery, males were removed from female cage.
During surgery, three ovaries either treated with 10mM of inhibitor or with 1%DMSO, as described previously in the drug treatment section, were placed in the intrabursal space of each ovary. Females were allowed a recovery period of six weeks. The recovery period was determined as being the amount of time needed for the implanted ovaries (relative age of 12 days old) to reach reproductive age if never remover from their physiological environment. After the recovery period females were house with black males. At 40 weeks of age, upon euthanasia, dissection was performed for visual confirmation of the presence of ovaries for both mock treated and treated.
Whole organ immunofluorescence
Ovaries cultured for seven days were fixed in freshly prepared 4%paraformaldehyde (PFA) /PBS at 4°C overnight (ON). Afterwards, tissues were washed and stored in 70% ethanol at 4°C until further processing.
Fixed ovaries were washed and left to equilibrate for a minimum of four hours in PBS before initializing whole-mount immunostaining protocol. In order to facilitate handling and tissue integrity, ovaries were kept in the culture insert throughout all the procedure. The ovaries were treated for four hours in permeabilization solution (PBS, 0.2% Polyvynal alcohol (PVA), 0.1% NaBH4-solution (Sigma) and 1.5% Triton X-100), than incubated for 24 hours in blocking solution (PBS, 0.1% Triton X-100, 0.15% Glycine pH7.4, 10% normal goat serum, 3% BSA, 0.2% sodium azide and 100 units/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml Fungizone). All the immunostaining and clearing was performed at room temperature (RT) with gentle rocking. Antibodies were diluted to appropriate concentration in the blocking solution. Primary antibodies (mouse anti-p63 (1:500, 4A4, Novus Biologicals); and rabbit anti-MVH (1:600, Abcam)) were incubated for four days. Afterwards, ovaries were washes with washing solution (PBS, 0.2% PVA and 0.15% triton X-100) for 10 hours than two times of two hours.
Secondary antibodies (1:1000 Alexa Fluor® secondary antibodies) were incubated for three days in a vial protected from light. Ovaries were washes with washing solution for three times of 12 hours (if needed DAPI 50ng/ml was added to the first wash).
Clearing, imaging, and oocyte quantification
Immunostained ovaries were cleared with modified, freshly-prepared ScaleS4 (0) reagent (40% D-(-)-sorbitol (w/v), 10% glycerol, 4M urea, 20% dimethylsufoxide, pH8.1 (HAMA et al. 2015) , gently mixed by inversion at 50°C for 30min and degassed prior to use). Solution was refreshed twice daily until tissue became transparent (usually two days). The insert was placed on top of a glass slide, and the membrane containing the cultured ovaries was carefully removed with a fine tip scalpel and placed on the slide.
Slides were imaged on an upright laser scanning Zeiss LSM880 confocal/multiphoton microscope, using a 10X NA 0.45 water immersion objective. For proper image stitching the adjacent images (tiles) were overlapped by 20%. The z-steps were set for 5µm between optical sections. Images were reconstructed, visualized and analyzed using Fiji-ImageJ (SCHINDELIN et al. 2012) .
Movies were made using the 3D project feature of Fiji-ImageJ (SCHINDELIN et al. 2012) . Oocyte quantification was performed in flattened maximum intensity projections of the Z-stacks image-series, using the "analyze particle" feature of Fiji-ImageJ.
Statistical analysis
Statistical analyses were done using JMP Pro12 software (SAS Inc., Cary, NC-USA, version 12.0.1). Fertility was analyzed using a mixed model with mother as random effect and ovary treatment as fixed effect. Least square (LS) means difference between litter sizes derived from treated vs non-treated ovaries was performed using the Student's t test. LS mean differences between follicle counts from the different treatment groups were tested using Tukey honest significance different (HSD). Western blot analysis of protein extracted from five dpp ovaries. Ovaries were incubated with the indicated concentrations of CHK2 inhibitor II (see Methods), and exposed or not to 3 Gy of γ-radiation. The immunoblot membrane was cut into two parts -one containing proteins >60 kDa, and the other <60kDa -and probed with anti-p63 and anti-p53, respectively. The >60 kDa portion was stripped and re-probed for the germ cell marker MVH. Arrowheads indicated the expected molecular weight of the phosphorylated form of TAp63 (upper), and non-phosphorylated TAp63 (lower). Fig.3 
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